Why couldn't they enroll patients x-US (perhaps some x-EU too) where I presume Nusinersen would be later to market? Given EU reimbursement timelines they could potentially get the majority in Europe and not have to resort to other territories.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.